- This meeting has passed.
Effectiveness, efficiency and highest scientific standards – the TARGIT-A trial comparing single-dose IORT with EBRT upheld expectations
October 13, 2020 @ 7:00 am - 11:00 am
The use of targeted intra-operative radiotherapy (TARGIT), as a single dose – with ZEISS INTRABEAM – directly after removal of a tumor, is confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). The TARGIT-A study further is the largest international multicenter study with a follow-up time of 8.6 years. In addition to its effectiveness, the IORT technique is demonstrating its cost efficiency. But will this be enough to now also develop further clinical treatment standards and reflect this in the guidelines?
Please join us in hearing the breast surgeon Professor Michael Alvarado, the radiation oncologists Professor William Small and Dr. Valery Uhl discussing this elemental question, based on this latest clinical milestone.
Tuesday, October 13, 2020
9:00 – 10:00 AM CEST | 3:00 – 04:00 AM EDT
4:00 – 5:00 PM CEST | 10:00 – 11:00 AM EDT
“Being part of a multi-site private practice, we have a lot going on and I rely on ANCO for its fantastic education, CME opportunities and access to local experts at speaking engagements. ANCO also looks out for our best interests with its advocacy efforts and practice management tools. I look to them as a go-to local resource. There’s no question that ANCO membership is a great value for all it provides. I’m proud to be on the board and part of this thriving organization.”
Zachary Koontz, MD
Pacific Cancer Care